Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Black raspberries under the microscope for prostate cancer prevention

NCT ID NCT01823562

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial studied how compounds from black raspberries are absorbed and processed in 60 men with prostate cancer who were scheduled for surgery. Participants ate a black raspberry confection and followed a special diet before surgery. The goal was not to treat cancer but to gather information that could guide future research on dietary prevention. No side effects were reported.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
black raspberry confection
What this could lead to
If successful, this could help design future studies on whether black raspberries might help prevent prostate cancer.
What could go wrong
This is a very early phase 1 trial focused on absorption and safety, not on treating or preventing cancer. It does not test whether black raspberries actually affect cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

60 people

The number who actually took part.

Started

Oct 2012

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have biopsy proven carcinoma of the prostate * Have chosen a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment options * Not be receiving neoadjuvant hormonal or chemotherapy (other clinical trials) * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Not currently taking berry dietary supplements, or "alternative" products (Acai berry, pomegranate, black raspberry, Optiberry, Juice Plus) * Have BUN/Cr (blood urea nitrogen and serum creatinine) within normal limits * Have liver enzymes within normal limits * Have complete blood count (CBC) within normal limits * Have prothrombin time/partial thromboplastin time (PT/PTT/INR) within normal limits * Voluntarily agree to participate and sign an informed consent document * Agree to have prostate biopsy blocks provided to the study for evaluation * Agree to consume a standardized vitamin and mineral supplement and avoid other nutrition, dietary, or alternative medications/supplements for the duration of the study * Agree to follow a controlled polyphenolic and/ or ellagitannin diet Exclusion Criteria: * Have an active malignancy other than prostate cancer that requires therapy * Have a prostate biopsy with less than 5% cancer involvement * Have a history of traumatic or surgical castration * Have a history of pituitary hormone diseases that currently require supplemental hormonal administration (thyroid hormones, adrenocorticotropic hormone \[ACTH\], growth hormone) or other endocrine disorders requiring hormone administration with the exception of diabetes and osteoporosis * Are taking certain medications; no concurrent finasteride (Proscar) or other hormonal agents for chemoprevention/treatment of benign prostate hyperplasia (BPH); utilizing prescription medications for urinary outlet obstructive symptoms will not be permitted; the use of non-prescription substances to improve urinary tract symptoms will not be permitted (i.e. Saw Palmetto, other herbal, alternative products) * Have a known allergy to black raspberries, corn, and wheat products or those who have never consumed any of these products * Have active metabolic or digestive illnesses such as malabsorptive disorders (Crohn's, Celiac disease, irritable bowel syndrome \[IBS\]), renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome * Have significant loss of gastrointestinal organs due to surgery, except for appendix * Have altered immunity such as autoimmune disorders, cancer, anemia, hemophilia, and blood dyscrasias * Have noticeable open lesions in the oral cavity, sores that have not healed for more than 2 months or have a history of leukoplakia, tumors of the buccal cavity, throat, and lips * Have difficulty swallowing (dysphagia), pain with swallowing (odynophagia), salivary gland dysfunction, or xerostomia (dry mouth) * Are taking medications that inhibit clotting (warfarin sodium) or using prescribed oral rinses (Peridex)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage I prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.